YOLFTbeta
64

Intech Biopharm Ltd

6461 · TWO · Healthcare / Biotechnology

24.80TWD-0.20 (-0.80%)

Price History

Full chart

Market Stats

Previous Close25.00
Open25.00
Day Range24.35 – 25.45
52-Week Range14.10 – 29.40
Volume97.80K
Market Cap2.92B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.69
Dividend Yield0.00%
Beta0.11
50-Day Avg25.47
200-Day Avg28.73

About

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Shuhui Chen
  • Employees96
  • HeadquartersNo. 36, Ruiguang Road, Taipei, Taiwan, 114, Taiwan
  • Websitehttps://www.intechbiopharm.com

Leadership

  • Ms. Shuhui ChenChief Accountant & Chief Corporate Governance Officer
  • Mr. Wei Xiu WuGeneral Manager
  • Mr. Qirui LiRepresentative
  • Mr. Xianzhi PiSpecial Assistant to the Chairman and Strategic Development Coordinator
  • Dr. Manish ChawlaPresident & Chief Scientific Officer
  • Ms. Chien-Yiu YangFinance Division Head

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue16.61M17.23M16.68M21.11M38.90M23.65M25.85M39.78M107.53M
Growth (%)-+3.77%-3.19%+26.50%+84.30%-39.21%+9.30%+53.90%+170.31%
Cost of Revenue7.06M8.32M162.71M160.00M158.27M170.91M189.84M197.40M218.47M
Gross Profit9.55M8.92M-146.02M-138.89M-119.37M-147.26M-164.00M-157.63M-110.94M
Gross Margin57.49%51.75%-875.23%-658.07%-306.87%-622.75%-634.48%-396.25%-103.18%
Operating Expense256.30M239.87M153.68M94.67M162.85M157.57M140.40M198.50M253.56M
Operating Income-246.75M-230.95M-299.71M-233.56M-282.22M-304.84M-304.40M-356.13M-364.50M
Operating Margin-1485.72%-1340.10%-1796.37%-1106.60%-725.51%-1289.11%-1177.68%-895.26%-338.99%
EBITDA-221.12M-199.78M-217.64M-148.61M-196.92M-219.48M-219.59M-246.70M-257.44M
EBITDA Margin-1331.42%-1159.22%-1304.48%-704.12%-506.23%-928.16%-849.56%-620.17%-239.42%
Net Income-239.31M-222.07M-311.42M-250.37M-301.76M-327.88M-337.99M-368.21M-389.03M
Net Income Margin-1440.96%-1288.59%-1866.60%-1186.25%-775.74%-1386.55%-1307.64%-925.63%-361.80%
R&D106.39M78.87M94.89M62.32M126.63M118.67M104.49M143.06M189.94M
R&D as % of Total Revenue640.58%457.63%568.75%295.29%325.54%501.86%404.25%359.63%176.65%
Interest Expense0735.00K19.31M16.81M19.54M23.04M33.59M34.16M33.52M
Interest Expense % of Total Revenue0.00%4.26%115.75%79.66%50.23%97.43%129.96%85.87%31.18%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.24B2.51B2.61B2.62B2.60B2.55B2.71B2.40B2.35B
Total Liabilities887.48M1.02B1.04B1.29B1.26B1.52B1.54B1.58B1.25B
Total Equity1.36B1.49B1.57B1.33B1.34B1.03B1.17B814.28M1.10B
Cash108.17M128.35M172.12M204.69M220.48M64.82M77.73M198.65M16.80M
Total Debt---1.18B1.15B1.41B1.44B--
Net Debt676.30M774.48M756.87M976.40M931.94M1.34B1.36B988.97M1.17B

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-145.29M-232.43M-189.09M-167.38M-200.61M-190.39M-204.13M-269.22M-361.13M
Investing Cash Flow-261.95M-204.60M-156.01M-42.20M-35.52M-203.98M---
Financing Cash Flow286.99M457.29M388.58M242.14M251.92M238.71M453.02M--
Capital Expenditure258.26M204.02M51.30M48.16M21.31M11.00M30.21M43.62M64.01M
Free Cash Flow-408.04M-437.27M-240.39M-215.54M-221.91M-201.39M-234.34M-312.84M-425.14M
FCF to OCF280.85%188.13%127.13%128.77%110.62%105.78%114.80%116.20%117.72%

Earnings

Report DateNov 29, 2017Feb 28, 2018May 30, 2018Aug 29, 2018Nov 28, 2018Feb 27, 2019May 29, 2019Aug 28, 2019Nov 27, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Dec 2, 2020Mar 3, 2021Jun 2, 2021Sep 1, 2021Dec 1, 2021Mar 2, 2022Jun 1, 2022Aug 31, 2022Nov 30, 2022Mar 1, 2023May 31, 2023
EPS Estimate-----------------------
EPS Actual-1.19-0.96-0.70-0.76-0.68-0.66-0.84-0.94-0.99-1.02-0.59-0.59-0.65-0.65-0.67-0.81-0.71-0.76-0.60-0.73-0.65-0.85-0.70
Surprise-----------------------
Timing-----------------------

Key Statistics & Ratios

Market Cap2.92B
Enterprise Value2.82B
Trailing P/E0.00
Forward P/E0.00
Price / Sales37.18
Price / Book1.83
EPS-4.69
Book Value8.11
Revenue (TTM)48.55M
Gross Profit (TTM)-185.67M
EBITDA-374.33M
Profit Margin0.00%
Operating Margin-517.16%
Return on Equity-47.57%
Return on Assets-11.57%
Shares Outstanding110.32M
Shares Float58.51M
Beta0.11
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 2, 2026618.578:1000